Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pluristem Therapeutics, a biotherapeutics company engaged in the commercialization of allogeneic cell therapy products, has appointed Frida Grynspan as its new vice president of R&D, effective March 1, 2009.
Subscribe to our email newsletter
Dr Grynspan will report directly to Zami Aberman, chairman, president and CEO of Pluristem.
Prior to joining Pluristem, Dr Grynspan served as vice president of R&D of a cell therapy company in Israel, where she was instrumental in bringing its first cell therapy product to a multinational, multi-center Phase III clinical trial and participated in the development of its pipeline.
Before that, Dr Grynspan served as a senior scientist at Intelligene, a developer of molecular biology diagnostic and therapeutic tools, and as an instructor and biochemist at Harvard Medical School.
Mr Aberman said: “Dr Grynspan has over 10 years of extensive professional experience in the field of human cell therapy and will be a valuable addition to Pluristem’s management and R&D team. Her experience will greatly benefit Pluristem, as the company is progressing towards its Phase I clinical trial with PLX-PAD and broadening its products’ pipeline.”